Eyegate Pharmaceuticals, Inc. (EYEG) Analysts See $-0.26 EPS; Allianzgi Convertible & Income Fund (NCV)’s Sentiment Is 0.65

February 13, 2018 - By Stephen Andrade

The stock increased 1.50% or $0.1 during the last trading session, reaching $6.77. About 632,859 shares traded or 50.68% up from the average. AllianzGI Convertible & Income Fund (NCV) has risen 19.58% since February 13, 2017 and is uptrending. It has outperformed by 2.88% the S&P500.

Analysts expect Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) to report $-0.26 EPS on February, 22.They anticipate $0.12 EPS change or 31.58% from last quarter’s $-0.38 EPS. After having $-0.24 EPS previously, Eyegate Pharmaceuticals, Inc.’s analysts see 8.33% EPS growth. The stock increased 2.27% or $0.02 during the last trading session, reaching $0.69. About 260,551 shares traded. Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) has declined 40.33% since February 13, 2017 and is downtrending. It has underperformed by 57.03% the S&P500.

E&G Advisors Lp holds 0.52% of its portfolio in AllianzGI Convertible & Income Fund for 163,272 shares. Vident Investment Advisory Llc owns 319,894 shares or 0.12% of their US portfolio. Moreover, Capital Investment Advisors Llc has 0.07% invested in the company for 136,722 shares. The California-based National Planning Corp has invested 0.07% in the stock. Next Financial Group Inc, a Texas-based fund reported 24,140 shares.

EyeGate Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing drug compositions and drug delivery systems for treating diseases and disorders of the eye. The company has market cap of $11.87 million. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including the treatment of ocular inflammation and pain in post-surgical cataract patients; and uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea. It currently has negative earnings. It is also developing the EyeGate Ocular Bandage Gel, a topically-applied eye drop formulation that has completed its first-in-man clinical trial for the management of corneal epithelial defects, as well as to accelerate re-epithelization of the ocular surface following surgery, injection, and other traumatic and non-traumatic conditions.

Among 2 analysts covering Eyegate Pharmaceuticals (NASDAQ:EYEG), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eyegate Pharmaceuticals had 2 analyst reports since November 12, 2015 according to SRatingsIntel. Maxim Group initiated it with “Buy” rating and $11 target in Thursday, November 12 report. Chardan Capital Markets initiated Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) on Wednesday, December 23 with “Buy” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: